サンプル依頼リスト カート
  • English
  • Korean
表紙：慢性気管支炎治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1352172

慢性気管支炎治療の世界市場-2023年～2030年

Global Chronic Bronchitis Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
慢性気管支炎治療の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の慢性気管支炎治療市場は、2022年に55億米ドルに達し、2023-2030年の予測期間中にCAGR 3.7％で成長し、2030年には73億米ドルに達すると予測されています。

世界の慢性気管支炎市場は、主に有病率の増加により、近年著しい成長を遂げています。慢性気管支炎は慢性閉塞性肺疾患（COPD）の一種で、世界第3位の死因であり、深刻な呼吸障害を引き起こします。主な原因はタバコの喫煙や大気汚染などですが、まれにα1アンチトリプシン欠損症と呼ばれる遺伝的疾患が慢性気管支炎を引き起こす一因となることもあります。

慢性気管支炎は通常、治すことはできませんが、症状を確認し、酸素療法、リハビリテーション、点鼻薬、気管支拡張薬、抗ヒスタミン薬、抗生物質、抗炎症薬などのさまざまな種類の薬剤によって管理することができます。治療薬は症状の重症度に応じて提案されます。全体として、市場は近年著しい成長を遂げており、今後数年間は拡大が見込まれています。

さらに、慢性気管支炎の有病率の増加、認知度の向上と早期診断、高齢化人口の増加、臨床試験の増加、タバコ喫煙例の増加とライフスタイルの変化、新規治療薬に対する需要の増加、技術進歩が、予測期間中に世界の慢性気管支炎治療市場を牽引すると予想される主な要因です。

ダイナミクス

新規治療薬に対する需要の増加が慢性気管支炎治療市場の成長を牽引

慢性気管支炎治療市場の分野では、新規治療薬に対する需要が継続的に増加しており、予測期間にわたって市場を牽引しています。慢性気管支炎の世界の有病率は継続的に増加しており、特にタバコの喫煙や大気汚染などの危険因子が原因となっています。診断される症例数が増加しているため、効果的な治療法や治療薬に対する需要が継続的に高まっています。新規の治療薬は、さまざまな剤形があります。

多くの研究センターや製薬会社は、慢性気管支炎をより良く管理するための革新的な薬剤や治療薬の開発に継続的に投資しています。革新的な治療薬には、気管支拡張薬、抗炎症薬、粘液溶解薬、およびより良い症状管理と疾患管理を提供できるその他の併用療法が含まれます。

臨床試験の増加が慢性気管支炎治療市場の成長を促進

慢性気管支炎治療の分野では、慢性気管支炎治療薬の使用に関する安全性の懸念や有効性を改善する臨床試験が増加しています。多くの臨床試験は、病気の管理における強化された結果を実証するために、治験薬をプラセボで評価することによって進められています。このような臨床試験は、医薬品、医療機器、その他の技術的治療法の技術革新を促進します。

例えば、2023年3月23日、サノフィは、慢性気管支炎を含む慢性閉塞性肺疾患（COPD）がコントロールされておらず、2型炎症のエビデンスがあり、現在最大限の標準的吸入療法（3剤併用療法）を受けている成人を対象に、デュピクセント（デュピルマブ）の治験薬としての使用をプラセボと比較評価する第3相試験を発表しました。デュピクセントは、COPDの中等度または重度の急性増悪（呼吸器症状の慢性的かつ急性的な悪化）を臨床的に意義のある高度に有意な減少を示した最初で唯一の生物学的製剤です。

臨床試験はまた、治療薬の安全性に関する貴重なデータを生み出し、エビデンスに基づいた医療の実践に貢献します。この臨床データは、多くのヘルスケア専門家が慢性気管支炎治療市場を管理する際に役立ちます。多くの臨床試験はまた、より良い管理のために強化された結果を示す薬剤クラスや他の組み合わせの組み合わせによって実施されています。

例えば、2023年4月11日、英国を拠点とするVerona Pharma社は、慢性気管支炎や肺気腫を含む慢性閉塞性肺疾患（COPD）の維持療法としてエンシフェントリン（Ensifentrine）を検討する第III相試験において、パートナーであるNuance Pharma社が最初の患者を投与したと発表しました。エンシフェントリンは、PDE3酵素とPDE4酵素の選択的二重阻害剤であり、気管支拡張作用と非ステロイド性抗炎症作用を併せ持ちます。

薬剤に伴う副作用が市場の成長を妨げる

慢性気管支炎治療薬に伴う副作用は、予測期間中、市場の妨げになると予想されます。重篤な副作用には、打撲、口腔感染症や嗄声、食欲増進、骨が弱くなったり細くなったりする（骨粗鬆症）などがあります。こうした副作用は、治療薬の使用に対する否定的な認識を生みます。この否定的な認識は、治療薬の有効性と安全性に対する信頼の低下につながり、その採用にさらに影響を及ぼします。

臨床試験中に確認された深刻な副作用は、医薬品開発、技術革新、規制当局の承認の遅れにさらにつながります。このような遅延は、新しい治療法や治療薬の入手を先延ばしにし、慢性気管支炎治療市場全体の成長にさらに影響を与える可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 新規治療薬に対する需要の増加
      • 臨床試験の増加
    • 抑制要因
      • 薬剤に伴う副作用
    • 機会
      • 技術進歩
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 治療タイプ別

  • 気管支拡張薬
    • β2アゴニスト
      • サルブタモール
      • サルメテロール
      • ホルモテロール
      • ビランテロール
      • その他
    • 抗コリン薬
      • イプラトロピウム
      • チオトロピウム
      • アクリジニウム
      • グリコピロニウム
    • テオフィリン
  • 抗炎症薬
    • 副腎皮質ステロイド
      • フルチカゾン（フロベント）
      • ブデソニド（パルミコート）
      • プレドニゾロン
      • その他
    • その他
  • 抗生物質
    • セファロスポリン
    • マクロライド系
    • ドキシサイクリン
    • アモキシシリン・クラブラン酸塩
    • フルオロキノロン系抗菌薬
    • その他
  • 酸素療法
  • 肺リハビリテーション
  • その他

第8章 投与経路別

  • 経口
  • 非経口
  • 経鼻

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 エンドユーザー別

  • 病院
  • リハビリセンター
  • 専門クリニック
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Bayer AG
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • AstraZeneca
  • Sanofi
  • Boehringer Ingelheim
  • Dr Reddy's Laboratories
  • GlaxoSmithKline
  • Teva Pharmaceuticals
  • Cipla
  • Pulmatrix
  • Nephron Pharmaceuticals

第14章 付録

目次
Product Code: PH6952

Overview

Global Chronic Bronchitis Treatment Market reached US$ 5.5 billion in 2022 and is expected to reach US$ 7.3 billion by 2030 growing with a CAGR of 3.7% during the forecast period 2023-2030.

The global chronic bronchitis market experiencing significant growth in recent years mainly owing to the increasing prevalence. Chronic bronchitis is a type of Chronic Obstructive Pulmonary Disease (COPD), a third leading cause of death worldwide, that causes severe breathing problems. The primary cause includes cigarette smoking and air pollution, but in rare situations, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis.

Chronic bronchitis usually cannot be cured but the symptoms can be identified and managed by oxygen therapy, rehabilitation, nasal sprays, and various types of drugs such as bronchodilators, anti-histamines, antibiotics, and anti-inflammatory drugs, among others. The therapeutics can be suggested based on the severity of the symptoms. Overall, the market is experiencing significant growth in recent years and is expected to increase in the coming years.

Moreover, owing to the increasing prevalence of chronic bronchitis, increasing awareness and early diagnosis, rising aging population, rising clinical trials, rising tobacco smoking cases and changing lifestyle, increasing demand for novel therapeutics, and technological advancements are the major factors expected to drive the global chronic bronchitis treatment market over the forecast period.

Dynamics

Increasing Demand for Novel Therapeutics Drives the Growth of the Chronic Bronchitis Treatment Market

There is a continuously increasing demand for novel therapeutics in the field of chronic bronchitis treatment market, which drives the market over the forecast period. The global prevalence of chronic bronchitis is continuously increasing, especially due to the risk factors such as tobacco smoking, and air pollution. As there is an increasing number of diagnosed cases, the demand for effective treatments and therapeutics continuously increases. The novel therapeutics may be available in different dosage forms.

Many research centers and pharmaceutical companies are continuously investing in the development of innovative drugs and therapeutics for the better management of chronic bronchitis. The innovations include bronchodilators, anti-inflammatory agents, mucolytics, and other combination treatments which can provide better symptom management and disease management.

Rising Clinical Trials Also Drive the Growth of the Chronic Bronchitis Treatment Market

There are rising clinical trials in the field of chronic bronchitis treatment that improve the safety concerns and effectiveness of the usage of chronic bronchitis therapeutics. Many clinical trials are going forward by evaluating the investigational drugs with a placebo to demonstrate enhanced results in the management of the disease. These clinical trials enhance innovations in drugs, medical devices, and other technological therapeutics.

For instance, on March 23, 2023, Sanofi announced the Phase 3 trial evaluating the investigational use of Dupixent (dupilumab) compared to placebo in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) including chronic bronchitis and evidence of type 2 inflammation. Dupixent is the first and only biologic to demonstrate a clinically meaningful and highly significant reduction in moderate or severe acute exacerbations of COPD (chronic and acute worsening of respiratory symptoms).

Clinical trials also generate valuable data about the safety of the therapeutics which contribute to evidence-based medical practices. This clinical data helps many healthcare professionals in the management of the chronic bronchitis treatment market. Many clinical trials are also conducted by the combination of drug classes and other combinations which shows enhanced results for better management.

For instance, on April 11, 2023, UK-based Verona Pharma announced that its partner Nuance Pharma dosed the first patient in its Phase III trial investigating ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema. Ensifentrine is a selective dual inhibitor of PDE3 and PDE4 enzymes, combining bronchodilator and non-steroidal anti-inflammatory activities.

Side Effects Associated with Drugs Will Hamper the Growth of the Market

The side effects associated with chronic bronchitis drugs are expected to hamper the market over the forecast period. The severe side effects may include bruising, oral infections and hoarseness, increased appetite, weak or thin bones (osteoporosis), and others. These side effects create a negative perception of the usage of therapeutics. This negative perception leads to decreased trust in the treatment's efficacy and safety, further impacting its adoption.

The severe adverse effects identified during clinical trials further leads to delays in drug development, innovations, and regulatory approvals. These delays have the ability to postpone the availability of new treatments and therapeutics, further affecting the overall growth of the chronic bronchitis treatment market.

Segment Analysis

The global chronic bronchitis treatment market is segmented based on treatment type, route of administration, distribution channel, end-user, and region.

The Bronchodilators from the Treatment Type Segment Accounted for Approximately 38.4% of the Chronic Bronchitis Market Share

Bronchodilators holds the largest market share in the chronic bronchitis treatment market over the forecast period for the management of the severity. They are very effective to provide rapid relief from symptoms such as shortness of breath, wheezing, and coughing, among others. Bronchodilators have the ability to quickly open up airways and making them a preferred choice for managing the severity of breathlessness. Even, the bronchodilators are also in combination with different classes for effective management.

For instance, on October 10, 2022, AeroRx Therapeutics is teaming up with Hcmed Innovations to develop a new therapeutic combination of different classes of bronchodilators medications that help to open up the airways and make breathing easier for the treatment of people with chronic bronchitis and emphysema.

Moreover, in some cases, patients with chronic bronchitis may experience acute exacerbations which leads to shortness of breath or severe breathlessness, in such cases the bronchodilators offer quick relief from the shortness of breath during these exacerbations, further improving patient comfort and reducing the need for urgent medical needs. Their wide availability and applicability for all age groups also helps to dominate the segment in the chronic bronchitis treatment market.

Geographical Penetration

North America Accounted for Approximately 39.2% of the Market Share in 2022, Owing to the Increasing Prevalence and Well-Established Healthcare Infrastructure

North America, usually has a high population and also there is a continuously increasing prevalence especially due to the high smoking rate and air pollution in the region. For instance, according to the National Institute of Health, in the United States, cigarette smoke is the main cause, and pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if inhaled.

For instance, according to the American Lung Association, in the United States, more than 12.5 million people have been diagnosed with COPD till November 2022, but millions more may have the disease without even knowing it.

North America especially in the United States and Canada has well-established and advanced healthcare infrastructure including hospitals, rehabilitation centers, specialty clinics, research centers, and among others. This enables them to manage severe conditions by developing innovative treatment options and attracting funding and investments, further driving the market in the region.

Competitive Landscape

The major global players in the chronic bronchitis treatment market include: Bayer AG, AstraZeneca, Sanofi, Boehringer Ingelheim, Dr Reddy's Laboratories, GlaxoSmithKline, Teva Pharmaceuticals, Cipla, Pulmatrix, and Nephron Pharmaceuticals among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global chronic bronchitis treatment market. The pandemic highlighted respiratory-related problems, which leads to early detection and diagnosis of any respiratory conditions including chronic bronchitis. And many clinical trials and research activities are temporarily disrupted or temporarily delayed which in turn results in a slow down of the introduction of novel therapeutics for the management of chronic bronchitis.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global chronic bronchitis treatment market. The conflict disrupted the supply chain of raw materials including different types of drugs and devices. And due to the less presence of the major global players in the chronic bronchitis market in the region, the conflict has a moderate impact.

By Treatment Type

  • Bronchodilators
  • Beta-2 Agonists
  • Salbutamol
  • Salmeterol
  • Formoterol
  • Vilanterol
  • Others
  • Anticholinergics
    • Ipratropium
    • Tiotropium
    • Aclidinium
    • Glycopyrronium
  • Theophylline
  • Anti-Inflammatory Drugs
  • Corticosteroids
  • Fluticasone (Flovent)
  • Budesonide (Pulmicort)
  • Prednisolone
  • Others
    • Others
    • Antibiotics
    • Cephalosporins
    • Macrolides
    • Doxycycline
    • Amoxicillin-Clavulanate
    • Fluoroquinolones
    • Others
    • Oxygen Therapy
    • Pulmonary Rehabilitation
    • Others

By Route of Administration

  • Oral
  • Parenteral
  • Nasal

By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By End User

  • Hospitals
  • Rehabilitation Centers
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On July 21, 2023, Hormosan Pharma GmbH, Lupin's wholly-owned subsidiary in Germany, announced the launch of Luforbec 100/6 (beclometasone 100µg / for moterol 6µg), a fixed combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema in Germany. Luforbec 100µg/6µg pMDI is the use of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) is suitable.
  • On March 30, 2023, UC Davis Health is turning to a digital health solution from Propeller Health to monitor treatment for high-risk patients with chronic obstructive pulmonary disease (COPD) including bronchitis and emphysema. UC Davis Health will provide the Propeller program including sensors, mobile app, a web portal, and personalized support to eligible patients, with eventual expansion to patients in other UC locations and UC affiliates. The sensors attach to a patient's inhaler to capture signals that record events, such as medication usage or respiration
  • On November 28, 2022, C4X Discovery Holdings and AstraZeneca entered into a licensing deal to develop an oral treatment for chronic bronchitis, emphysema, and other inflammatory and respiratory illnesses, the companies announced. The partners will focus on developing C4XD's NRF2 Activator program with an initial focus on COPD. The agreement could reach $402 million.

Why Purchase the Report?

  • To visualize the global chronic bronchitis treatment market segmentation based on treatment type, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of chronic bronchitis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global chronic bronchitis treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Novel Therapeutics
      • 4.1.1.2. Rising Clinical Trials
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with Drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological Advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Bronchodilators *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Beta-2 Agonists
      • 7.2.3.1. Salbutamol
      • 7.2.3.2. Salmeterol
      • 7.2.3.3. Formoterol
      • 7.2.3.4. Vilanterol
      • 7.2.3.5. Others
    • 7.2.4. Anticholinergics
      • 7.2.4.1. Ipratropium
      • 7.2.4.2. Tiotropium
      • 7.2.4.3. Aclidinium
      • 7.2.4.4. Glycopyrronium
    • 7.2.5. Theophylline
  • 7.3. Anti-Inflammatory Drugs
    • 7.3.1. Corticosteroids
      • 7.3.1.1. Fluticasone (Flovent)
      • 7.3.1.2. Budesonide (Pulmicort)
      • 7.3.1.3. Prednisolone
      • 7.3.1.4. Others
    • 7.3.2. Others
  • 7.4. Antibiotics
    • 7.4.1. Cephalosporins
    • 7.4.2. Macrolides
    • 7.4.3. Doxycycline
    • 7.4.4. Amoxicillin-Clavulanate
    • 7.4.5. Fluoroquinolones
    • 7.4.6. Others
  • 7.5. Oxygen Therapy
  • 7.6. Pulmonary Rehabilitation
  • 7.7. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral
  • 8.4. Nasal

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Rehabilitation Centers
  • 10.4. Specialty Clinics
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Bayer AG *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. AstraZeneca
  • 13.3. Sanofi
  • 13.4. Boehringer Ingelheim
  • 13.5. Dr Reddy's Laboratories
  • 13.6. GlaxoSmithKline
  • 13.7. Teva Pharmaceuticals
  • 13.8. Cipla
  • 13.9. Pulmatrix
  • 13.10. Nephron Pharmaceuticals

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us